Editing Mifepristone (section)

==Research==
The original target for the research group was the discovery and development of compounds with antiglucocorticoid properties.<ref>{{cite journal |vauthors= Hazra BG, Pore VS |title= Mifepristone (RU-486), the recently developed antiprogesterone drug and its analogues |journal= J Indian Inst Sci |year= 2001 |volume= 81 |pages= 287–298 | url = https://journal.iisc.ac.in/index.php/iisc/article/view/2024/2089 }}</ref>

Use of mifepristone as a [[Cervical dilation|cervical ripening]] agent has been described.<ref name="pmid16647925">{{cite journal |vauthors= Clark K, Ji H, Feltovich H, Janowski J, Carroll C, Chien EK |title= Mifepristone-induced cervical ripening: structural, biomechanical, and molecular events |journal= Am. J. Obstet. Gynecol. |volume= 194 |issue= 5 |pages= 1391–8 |date= May 2006 |pmid= 16647925 |doi= 10.1016/j.ajog.2005.11.026 }}</ref> The medication has been studied as an antiandrogen in the treatment of [[prostate cancer]].<ref name="pmid18399827">{{cite journal | vauthors = Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, Barb D, Mantzoros C, Gelmann EP, Balk SP | title = A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones | journal = BJU Int. | volume = 101 | issue = 9 | pages = 1084–9 | year = 2008 | pmid = 18399827 | doi = 10.1111/j.1464-410X.2008.07509.x | s2cid = 205538600 }}</ref><ref name="AdisInsight">{{Cite web | url=http://adisinsight.springer.com/drugs/800001657 | title=Mifepristone - Corcept Therapeutics - AdisInsight | access-date=27 December 2017 | archive-date=27 December 2017 | archive-url=https://web.archive.org/web/20171227235346/http://adisinsight.springer.com/drugs/800001657 | url-status=live }}</ref> Mifepristone showed no detectable anti-HIV activity in clinical trials.<ref name="schimmer"/><ref name="chabbert-buffet"/><ref name="pmid17932493">{{cite journal | vauthors = Flexner C |title= HIV drug development: the next 25 years |journal= Nat Rev Drug Discov |volume= 6 |issue=12 |pages= 959–66 |date= December 2007 |pmid= 17932493 |doi= 10.1038/nrd2336 |s2cid= 31261997 }}</ref><ref name="tang">{{cite journal |vauthors= Tang OS, Ho PC |year=2006 |title= Clinical applications of mifepristone |journal= Gynecol Endocrinol |volume=22 |issue=12 |pages= 655–9 |pmid= 17162706 |doi= 10.1080/09513590601005946|s2cid=23295715 }}</ref>

Mifepristone showed initial promise in [[psychotic major depression]], a difficult-to-treat form of depression,<ref name="pmid11593077">{{cite journal | vauthors = Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF | title = Rapid reversal of psychotic depression using mifepristone | journal = Journal of Clinical Psychopharmacology | volume = 21 | issue = 5 | pages = 516–21 | date = October 2001 | pmid = 11593077 | doi = 10.1097/00004714-200110000-00009 | s2cid = 3067889 }}</ref><ref name="Howland_2013">{{cite journal | vauthors = Howland RH | title = Mifepristone as a therapeutic agent in psychiatry | journal = Journal of Psychosocial Nursing and Mental Health Services | volume = 51 | issue = 6 | pages = 11–4 | date = June 2013 | pmid = 23814820 | doi = 10.3928/02793695-20130513-01 }}</ref> but a phase-III clinical trial was terminated early due to lack of efficacy.<ref>{{cite news | vauthors = Gard D | work = Fierce Biotech | date = 7 May 2014 | url = http://www.fiercebiotech.com/story/corcept-tanks-depression-drug-comes-short-phase-iii/2014-05-07 | title = Corcept tanks as depression drug comes up short in Phase III | archive-url = https://web.archive.org/web/20160302191829/http://www.fiercebiotech.com/story/corcept-tanks-depression-drug-comes-short-phase-iii/2014-05-07 | archive-date = 2 March 2016 }}</ref> It has been studied in bipolar disorder,<ref>{{cite journal | vauthors = Soria V, González-Rodríguez A, Huerta-Ramos E, Usall J, Cobo J, Bioque M, Barbero JD, García-Rizo C, Tost M, Monreal JA, Labad J | title = Targeting hypothalamic-pituitary-adrenal axis hormones and sex steroids for improving cognition in major mood disorders and schizophrenia: a systematic review and narrative synthesis | journal = Psychoneuroendocrinology | volume = 93 | pages = 8–19 | date = July 2018 | pmid = 29680774 | doi = 10.1016/j.psyneuen.2018.04.012 | s2cid = 5041081 }}</ref> post traumatic stress disorder,<ref name="Howland_2013" /> and anorexia nervosa.<ref>{{cite journal | vauthors = Bou Khalil R, Souaiby L, Farès N | title = The importance of the hypothalamo-pituitary-adrenal axis as a therapeutic target in anorexia nervosa | journal = Physiology & Behavior | volume = 171 | pages = 13–20 | date = March 2017 | pmid = 28043861 | doi = 10.1016/j.physbeh.2016.12.035 | s2cid = 6329552 }}</ref>